ArticleJournal of medical case reports2026
Breaking the serologic rule: chronic hepatitis B with simultaneous HBsAg and anti-HBs positivity-a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hepatitis B virus (HBV) infection continues to pose a significant global disease burden, because of its potential progression to liver cirrhosis and hepatocellular carcinoma (HCC). Worldwide, more than 250 million individuals are estimated to be living with chronic HBV infection. Under standard serologic interpretation, the presence of hepatitis B surface antigen (HBsAg) signifies ongoing infection, whereas antibodies to hepatitis B surface antigen (anti-HBs) are generally associated with viral clearance or protective immunity. The simultaneous presence of both markers is rare and may lead to misinterpretation of serologic results, particularly when identified incidentally during routine screening in a primary care settings. CASE PRESENTATION: We describe a 60-year-old Saudi woman with an asymptomatic chronic HBV infection incidentally identified during routine pre-colonoscopy screening in a primary care setting. Laboratory testing revealed reactive HBsAg, total anti-HBc positivity, reactive anti-HBs titer, and HBV DNA level was 275 IU/mL consistent with low-level viremia. Liver enzymes were mildly elevated on prior testing subsequently normalized on follow- up. Transient elastography demonstrated no evidence of hepatic fibrosis or steatosis. The patient had no history of HBV vaccination, blood transfusions, liver disease, or recognized high-risk exposures, including intravenous drug use or high-risk sexual or household contact.
conclusionThis case highlights a diagnostic pitfall in HBV serology, as concurrent HBsAg and anti-HBs positivity does not indicate viral clearance and may reflect immune escape mutations, viral heterogeneity, or host immune factors. Recognition of this rare serologic profile is particularly important for primary care physicians, as accurate interpretation requires integration of serologic, virologic, and clinical data, particularly in asymptomatic patients identified through routine screening. This ensure appropriate diagnosis, long-term surveillance, and risk stratification. Clinicians should remain vigilant when encountering this rare serologic profile to guide appropriate referral and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.